This launch supports Lupin's ongoing expansion in the U.S. generics market and enhances its footprint in the oral anti-diabetic segment. Lupin operates globally, with a presence in over 100 markets ...

Predicting Bioequivalence During Generic Drug Formulation. Small variations in formulation can affect bioequivalence. However ...

Merck built a wall of patents to keep a cancer drug's price – and its profits – high. Hospitals often add to the cost for ...

ANI Pharmaceuticals, Inc. (ANI or the Company) (Nasdaq: ANIP) today announced the launch of Carbamazepine Extended-Release Capsules, 100 mg, 200 mg and 300 mg. ANI’s Carbamazepine Extended-Release ...

U.S. regulators have withdrawn their approval of a GSK Plc drug that the Trump administration had promoted as a treatment for ...

Three questions can help patients get a better handle on drug and health care options. But many Americans still hold back ...

Eli Lilly loses share in India’s GLP‑1 market as cheap semaglutide generics surge, while Novo holds steady after deep price ...

NEW DELHI – Obesity emerged as a central focus of public health policy in India in 2025, driven by a major overhaul of clinical definitions, a surge in new weight loss medications and a series of ...

Generic dapagliflozin is now approved for adults with type 2 diabetes, though current labeling excludes chronic kidney disease and pediatric use.

Why do drugs cost so freaking much? And it’s a complicated question. There are a bunch of reasons — to be sure. But in our reporting over the years, like our stories on insulin and tuberculosis drugs, ...

Congress is also taking notice. On Feb. 4, the House passed PBM reform as part of a $1.2 trillion funding bill. The legislation imposes transparency requirements and prohibits PBMs from linking their ...